Concepedia

Publication | Open Access

Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study †

DOIFull Paper Access

156

Citations

30

References

2008

Year

Luc F. Van Gaal, André Scheen, Aila Rissanen, Stephan Rössner, Corinne Hanotin, Olivier Ziegler
European Heart Journal

Abstract

Rimonabant 20 mg over 2 years promoted clinically relevant and durable weight loss and improvements in cardiometabolic risk factors.

References

YearCitations

Page 1